Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment: real-life data from the German cutaneous lymphoma network
<b><i>Background:</i></b> Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an increased risk...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
Dermatology
Year: 2022, Jahrgang: 238, Heft: 3, Pages: 498-506 |
| ISSN: | 1421-9832 |
| DOI: | 10.1159/000517830 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000517830 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/517830 
|
| Verfasserangaben: | Christoph Blazejak, Rene Stranzenbach, Janika Gosman, Thilo Gambichler, Ulrike Wehkamp, Sarja Stendel, Claus-Detlev Klemke, Marion Wobser, Joanna Olk, Jan P. Nicolay, Maria Weyermann, Rudolf Stadler, Chalid Assaf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1827606002 | ||
| 003 | DE-627 | ||
| 005 | 20230601120550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221216s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000517830 |2 doi | |
| 035 | |a (DE-627)1827606002 | ||
| 035 | |a (DE-599)KXP1827606002 | ||
| 035 | |a (OCoLC)1361670202 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Blazejak, Christoph |e VerfasserIn |0 (DE-588)1159647313 |0 (DE-627)1022299980 |0 (DE-576)505153947 |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment |b real-life data from the German cutaneous lymphoma network |c Christoph Blazejak, Rene Stranzenbach, Janika Gosman, Thilo Gambichler, Ulrike Wehkamp, Sarja Stendel, Claus-Detlev Klemke, Marion Wobser, Joanna Olk, Jan P. Nicolay, Maria Weyermann, Rudolf Stadler, Chalid Assaf |
| 264 | 1 | |c 2022 | |
| 264 | 4 | |c September 2, 2021 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.12.2022 | ||
| 520 | |a <b><i>Background:</i></b> Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an increased risk for myelosuppression and severe infections. <b><i>Objectives:</i></b> We investigated in this retrospective study the effect of low-dose gemcitabine in pretreated advanced-stage CTCL and in blastic plasmacytoid dendritic cell neoplasia (BPDCN) regarding overall response (OR), progression-free survival (PFS), and AE. <b><i>Material and Methods:</i></b> A retrospective, multicenter study was conducted on 64 CTCL and BPDCN patients treated with gemcitabine in average absolute dosage of 1,800 mg/m<sup>2</sup> per cycle, which is 50% lower compared to standard dosage of 3,600 mg/m<sup>2</sup> per cycle (1,200 mg/m<sup>2</sup> day 1, 8, 15). Evaluation of response to therapy and AE was done 4-6 weeks after the sixth cycle. <b><i>Results:</i></b> OR was 62% with 11% demonstrating a complete response. The median time of PFS was 12 months and median time to next treatment was 7 months. Only 3/63 patients showed serious side effects, e.g., port infection or acute renal failure. Almost 73% of the patients experienced minor to moderate side effects (CTCAE grade 0-2). Fatigue (27.2%), fever (22.7%), and mild blood count alteration (18.2%) were the most common AE. <b><i>Conclusions:</i></b> This retrospective analysis supports the use of low-dose gemcitabine therapy in CTCL, demonstrating with 62% OR and PFS of 12 months an almost identical response rate and survival as compared to the standard dose therapy reported in previous studies but with a significantly improved safety profile and tolerability. | ||
| 700 | 1 | |a Stranzenbach, René |d 1980- |e VerfasserIn |0 (DE-588)143751263 |0 (DE-627)704591901 |0 (DE-576)338714731 |4 aut | |
| 700 | 1 | |a Gosman, Janika |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gambichler, Thilo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wehkamp, Ulrike |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stendel, Sarja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Klemke, Claus-Detlev |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wobser, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Olk, Joanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nicolay, Jan Peter |d 1981- |e VerfasserIn |0 (DE-588)138614474 |0 (DE-627)604867352 |0 (DE-576)308046188 |4 aut | |
| 700 | 1 | |a Weyermann, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stadler, Rudolf |e VerfasserIn |0 (DE-588)1155182782 |0 (DE-627)1016515197 |0 (DE-576)501454640 |4 aut | |
| 700 | 1 | |a Assaf, Chalid |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatology |d Basel : Karger, 1893 |g 238(2022), 3 vom: Mai, Seite 498-506 |h Online-Ressource |w (DE-627)300190999 |w (DE-600)1482189-8 |w (DE-576)112438156 |x 1421-9832 |7 nnas |a Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment real-life data from the German cutaneous lymphoma network |
| 773 | 1 | 8 | |g volume:238 |g year:2022 |g number:3 |g month:05 |g pages:498-506 |g extent:9 |a Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment real-life data from the German cutaneous lymphoma network |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000517830 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.karger.com/Article/FullText/517830 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221216 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 138614474 |a Nicolay, Jan Peter |m 138614474:Nicolay, Jan Peter |d 60000 |d 61900 |e 60000PN138614474 |e 61900PN138614474 |k 0/60000/ |k 1/60000/61900/ |p 10 | ||
| 999 | |a KXP-PPN1827606002 |e 4234022152 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1827606002"],"doi":["10.1159/000517830"]},"recId":"1827606002","name":{"displayForm":["Christoph Blazejak, Rene Stranzenbach, Janika Gosman, Thilo Gambichler, Ulrike Wehkamp, Sarja Stendel, Claus-Detlev Klemke, Marion Wobser, Joanna Olk, Jan P. Nicolay, Maria Weyermann, Rudolf Stadler, Chalid Assaf"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"9 S."}],"relHost":[{"part":{"issue":"3","pages":"498-506","text":"238(2022), 3 vom: Mai, Seite 498-506","extent":"9","volume":"238","year":"2022"},"title":[{"title_sort":"Dermatology","title":"Dermatology","subtitle":"international journal for clinical and investigative dermatology ; official organ of the Swiss Society for Dermatology and Syphiligraphy ; official organ of the Belgian Royal Society for Dermatology and Syphiligraphy"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment real-life data from the German cutaneous lymphoma networkDermatology","titleAlt":[{"title":"Dermatologische Zeitschrift"},{"title":"Dermatologica"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedDisp":"1893-","publisher":"Karger","dateIssuedKey":"1893","publisherPlace":"Basel ; Freiburg, Br. [u.a.]"}],"note":["Gesehen am 19.01.15","Ungezählte Beil.: Supplement"],"pubHistory":["1.1893/94 -"],"id":{"eki":["300190999"],"issn":["1421-9832"],"zdb":["1482189-8"]},"recId":"300190999"}],"title":[{"title_sort":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment","title":"Clinical outcomes of advanced-stage cutaneous lymphoma under low-dose gemcitabine treatment","subtitle":"real-life data from the German cutaneous lymphoma network"}],"person":[{"family":"Blazejak","given":"Christoph","role":"aut","display":"Blazejak, Christoph"},{"display":"Stranzenbach, René","role":"aut","given":"René","family":"Stranzenbach"},{"family":"Gosman","given":"Janika","display":"Gosman, Janika","role":"aut"},{"family":"Gambichler","given":"Thilo","display":"Gambichler, Thilo","role":"aut"},{"display":"Wehkamp, Ulrike","role":"aut","family":"Wehkamp","given":"Ulrike"},{"given":"Sarja","family":"Stendel","display":"Stendel, Sarja","role":"aut"},{"role":"aut","display":"Klemke, Claus-Detlev","family":"Klemke","given":"Claus-Detlev"},{"display":"Wobser, Marion","role":"aut","family":"Wobser","given":"Marion"},{"display":"Olk, Joanna","role":"aut","family":"Olk","given":"Joanna"},{"family":"Nicolay","given":"Jan Peter","role":"aut","display":"Nicolay, Jan Peter"},{"given":"Maria","family":"Weyermann","display":"Weyermann, Maria","role":"aut"},{"family":"Stadler","given":"Rudolf","role":"aut","display":"Stadler, Rudolf"},{"role":"aut","display":"Assaf, Chalid","given":"Chalid","family":"Assaf"}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"2022"}],"note":["Gesehen am 16.12.2022"]} | ||
| SRT | |a BLAZEJAKCHCLINICALOU2022 | ||